Using Text Messages to Improve COVID-19 Vaccination Uptake

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-11

Study Completion Date

2022-05-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

COVID-19 vaccinations significantly reduce the risk of getting seriously ill or dying from COVID-19. Since December 2020, the UK has rolled out vaccinations according to the Joint Committee for Vaccinations and Immunity (JCVI) priority groups. However, despite data indicating that more than 90% of the UK population intends to get vaccinated, there are geographical and ethnic variations in vaccination acceptance. As younger cohorts with lower risk from COVID-19 become eligible for vaccination, it is expected that uptake rates may also be lower than they have been in previous cohorts.

It was recently announced that a national NHS text message service will be introduced to invite individuals eligible for the COVID-19 vaccine to book a vaccination appointment. Many GP practices and CCGs have already implemented text messages to invite eligible residents and patients for the vaccine.

However, recent research has shown that the message content of text messages inviting members of the public to other preventative health opportunities (e.g. personalised messages and GP-endorsements in cancer screening) can impact uptake.

This 3-arm randomised controlled trial will be conducted across the Central London (CL) Clinical Commissioning Group (CCG) which to-date has seen the lowest rates of COVID-19 vaccination uptake in the country. The study aims to investigate the most effective text message strategy to inform local, regional and national practice.

The intervention text message content to be tested is informed by behavioural science theory is personalised to include the recipient's name and GP practice name. All patients in the Central London CCG who are unvaccinated, aged 18-49, who have not declined the vaccine will be included as their cohort becomes eligible for vaccination according to the JCVI guidelines. The trial will compare the uptake of the COVID-19 vaccination by trial arm at 3 and 8 weeks after the intervention is deployed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 and Vaccination Attitudes

NCT04352582

COVID-19

COMPLETED

Group Intervention on Vaccine Confidence

NCT05891626

Vaccination Refusal

UNKNOWN NA

Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine

NCT05085613

Beliefs

COMPLETED NA

Testing a Personalized Normative Feedback Intervention for Vaccine Hesitancy

NCT05787015

COVID-19 Vaccine Hesitancy

UNKNOWN NA

COVID-19 Booster Incentives

NCT05648773

Booster Message Booster Message + Financial Incentive

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The COVID-19 vaccine is an effective way to reduce morbidity and mortality from COVID-19. Increasing uptake of the COVID-19 vaccine is a major public health priority. People's willingness to receive the COVID- 19 vaccine in the UK has been at record highs - 9 in 10 people said they would receive it when the NHS notifies them that it is their turn. However, evidence suggests that willingness to get vaccinated is lower amongst younger age groups and BAME populations. Additionally, high willingness to be vaccinated may not translate into high uptake, particularly as the vaccine rollout extends to younger, less vulnerable cohorts.

Uptake of the COVID-19 vaccine may be influenced by many factors, including personal beliefs such as perceived low personal risk from COVID-19, perceived social and cultural norms or a concerns around vaccine safety or efficacy. Additionally, process barriers, such as the effort required to attend an appointment may reduce vaccine uptake. With more than 95% of UK households having a mobile phone, text messages can be an effective way to improve uptake of healthcare services and medicine adherence. In particular, recent research has shown that reminder text messages about flu vaccination appointments can improve uptake by up to 10%, and that some messages may be more effective for specific groups. However, more research is needed to maximise the effectiveness of messages to increase uptake of the COVID-19 vaccine specifically and to explore how the effectiveness of messaging differs across different age and ethnicity groups.

The proposed research will determine which message strategy increases COVID-19 vaccine vaccination rates in the cohort aged between 18 and 49 years old as they become eligible for the vaccine according to JCVI categories.

During the trial, each cohort that newly becomes eligible to be vaccinated will be randomised to one of the five trial text message strategies.

The trial arms will include the current practice text message invitation which will act as the control and four intervention trial arms. The intervention text message strategies and message content have been based on behavioural science theory.

The usual care team will deploy the text messages according to the trial arm allocation. The vaccination status will be recorded in the patients electronic health record (EHR) as per usual practice. Researchers will have access to the pseudonymised datasets through a secure data platform which only holds pseudonomised data (see data Study Procedure section).

Analysis will measure and compare the vaccination uptake across trial arms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

3-armed parallel randomised controlled trial

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

The researcher conducting the data analysis will do so using a trial arm code. They will not have the key to unlock which trial arm is which.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1 - Control SMS

Control (current practice) text message invitation

Group Type ACTIVE_COMPARATOR

Text message content

Intervention Type BEHAVIORAL

Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.

Arm 2 - Behavioural Science informed SMS content

Experimental text message invitation

Group Type EXPERIMENTAL

Text message content

Intervention Type BEHAVIORAL

Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.

Arm 3 - Pre-alert and behavioural science informed SMS content

Two text messages, including a pre-alert SMS and the text message intervention in trial arm 2.

Group Type EXPERIMENTAL

Text message content

Intervention Type BEHAVIORAL

Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Text message content

Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Residents registered with a GP practice in the Central London (Westminster) Clinical Commissioning Group (CCG)
* Age 18-49
* Not previously invited for COVID-19 vaccination

Exclusion Criteria

* Patients who have notified their GP that they wish to decline the COVID-19 vaccination.
* Patients' whose medical records report a severe allergy to medicines (as per the JCVI guidance)

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes